TORONTO, Oct. 24, 2012 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce that it has appointed Trapollo LLC ("Trapollo") as its non-exclusive agent for sales of Biosign software products (the "Products") within the contiguous 48 United States.
Trapollo is a leading provider of telehealth and remote monitoring technology, offering U.S. clients a complete suite of Remote Health Monitoring (RHM) solutions including medical devices, software, consulting, implementation and supply chain services to guide organizations in developing, deploying and maintaining best-in-class remote healthcare programs. Trapollo has a sales and fulfillment network that covers all 48 contiguous U.S. states. They deliver a "product neutral" set of solutions, which allows them to present Biosign's feature-rich FDA-cleared Healthanywhere™ products to large insurance and hospital customers. On August 22, 2012, Trapollo received the "2012 North American Frost & Sullivan Award for Customer Value Enhancement" for setting a new standard for quality in remote monitoring in the home.
Trapollo will primarily sell the Healthanywhere™ Health-At-Home™ product group, which includes our unique software optimized for home users. A 2011 study conducted in Ontario by WeCare™ Health Services found that 96% of patients using the Biosign system were maintained in their homes instead of requiring expensive nursing home care while patients using Health-At-Home™ saw a 70% decrease in slip-and-fall accidents. Overall the Healthanywhere™ solution received an 88% satisfaction rating from patients. (For details of this study please go to www.biosign.com/white-papers.apsx)
Healthanywhere™ software is FDA-cleared for sale in the United States. Biosign expects to begin jointly marketing Health-At-Home™ products with Trapollo immediately by approaching existing and prospective U.S. based Healthanywhere™ customers with an enhanced offering.
Biosign's CEO Robert Kaul stated: "This new alliance with Trapollo allows us to immediately deploy our leading-edge Cloud Diagnostics™ (CloudDX) solutions to significant customer segments in the continental U.S. market with a partner that satisfies Biosign's rigorous service standards in terms of end customer fulfillment and logistics. In addition to sales generated by our relationship with Trapollo, Biosign will also focus internal sales and marketing resources on expanding its Canadian and U.S. eHealth business substantially going forward. Telemedicine is projected by iData* to become a $3 billion business in North America by 2015. Alongside partners like Trapollo, we expect to supply a substantial portion of that market."
*iData "Markets for Patient Monitoring Equipment & Devices 2012" Report March 2012
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled health information products. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for clinical decision support, self-care, wellness and disease management, while its Healthanywhere™ software suite offers industry-leading remote patient monitoring solutions. For more information on Biosign, please visit www.biosign.com.
About Trapollo LLC.
Trapollo LLC is a leading service provider of remote health monitoring managed services for chronic disease management, independent living, and employer health and wellness programs. With offices in Northern Virginia, Trapollo is focused on the explosive field of Telehealth. Trapollo currently supports thousands of video-enabled in-home monitoring devices nationwide for large insurance providers, hospitals & health systems and government agencies. Additionally, Trapollo is focused on marketing its services to senior & assisted living communities and self-insured employers. For more information about Trapollo please go to www.trapollo.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Robert Kaul, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234
Email: [email protected]
John Aldridge, COO
Phone: (703) 434-3665
Email: [email protected]